DAFNA Capital Management LLC lifted its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX) by 68.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 373,409 shares of the biopharmaceutical company’s stock after purchasing an additional 151,671 shares during the quarter. Ardelyx comprises 1.4% of DAFNA Capital Management LLC’s portfolio, making the stock its 26th largest position. DAFNA Capital Management LLC owned approximately 0.79% of Ardelyx worth $1,904,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the company. Perceptive Advisors LLC increased its position in shares of Ardelyx by 2.7% during the 1st quarter. Perceptive Advisors LLC now owns 1,886,196 shares of the biopharmaceutical company’s stock valued at $23,860,000 after purchasing an additional 50,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Ardelyx by 3.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,277,634 shares of the biopharmaceutical company’s stock worth $6,516,000 after acquiring an additional 48,077 shares in the last quarter. Marshall Wace North America L.P. boosted its stake in shares of Ardelyx by 2.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 807,246 shares of the biopharmaceutical company’s stock worth $4,036,000 after acquiring an additional 16,764 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Ardelyx during the 1st quarter worth $10,276,000. Finally, Northern Trust Corp boosted its stake in shares of Ardelyx by 2.8% during the 2nd quarter. Northern Trust Corp now owns 367,753 shares of the biopharmaceutical company’s stock worth $1,876,000 after acquiring an additional 9,941 shares in the last quarter. Institutional investors and hedge funds own 78.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Marea Informative and is the property of of Marea Informative. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at http://www.mareainformativa.com/dafna-capital-management-llc-purchases-151671-shares-of-ardelyx-inc-ardx/117566/.

Several brokerages have recently commented on ARDX. Citigroup Inc. raised their target price on Ardelyx from $14.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald set a $12.00 target price on Ardelyx and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub raised Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Zacks Investment Research cut Ardelyx from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, ValuEngine raised Ardelyx from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $17.40.

Ardelyx, Inc. (NASDAQ:ARDX) traded down 6.731% during trading on Friday, hitting $7.275. The stock had a trading volume of 3,027,135 shares. Ardelyx, Inc. has a 12-month low of $4.05 and a 12-month high of $16.30. The stock has a 50 day moving average price of $5.58 and a 200 day moving average price of $6.99. The company’s market capitalization is $345.16 million.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.09. Equities research analysts forecast that Ardelyx, Inc. will post ($2.22) earnings per share for the current year.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Stock Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related stocks with our FREE daily email newsletter.